Sevelamer Carbonate
Rank #167 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$95.6M
Total Cost
277,192
Total Claims
$95.6M
Total Cost
6,867
Prescribers
$345
Cost per Claim
59,506
Beneficiaries
423,070
30-Day Fills
$14K
Avg Cost/Provider
40
Avg Claims/Provider
Share of Medicare Part D Spending
0.03%
of total Medicare Part D spending
$95.6M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $95.6M total
Top Prescribers of Sevelamer Carbonate
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Deno Kang | Internal Medicine | Artesia, CA | 123 | $189K |
| 2 | Thong Do | Internal Medicine | Hanford, CA | 165 | $173K |
| 3 | Amy Matayoshi | Nephrology | Oceanside, CA | 49 | $165K |
| 4 | Mohsen El Ramah | Internal Medicine | El Centro, CA | 62 | $163K |
| 5 | Thu Nguyen | Physician Assistant | Westminster, CA | 71 | $158K |
| 6 | Curtis Lee | Nephrology | Hilo, HI | 41 | $157K |
| 7 | Vijay Koka | Nephrology | Pasadena, TX | 305 | $153K |
| 8 | Ratnaji Nallamothu | Nephrology | Sacramento, CA | 46 | $148K |
| 9 | Susan Chang | Nephrology | Camarillo, CA | 175 | $142K |
| 10 | Fred Lui | Nephrology | San Francisco, CA | 46 | $136K |
| 11 | Melody Dumlao | Nephrology | Porterville, CA | 78 | $135K |
| 12 | Chalit Wanthakawikran | Nephrology | Laredo, TX | 40 | $135K |
| 13 | Anthony Blalock | Nephrology | Lafayette, LA | 50 | $130K |
| 14 | Shahid Hussain | Nephrology | El Centro, CA | 51 | $129K |
| 15 | Anjali Saxena | Nephrology | San Jose, CA | 40 | $128K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 164 | Guselkumab (Tremfya) | $97.1M | 7,102 |
| 165 | Levetiracetam (Levetiracetam) | $96.1M | 1,723,736 |
| 166 | Oxycodone Myristate (Xtampza Er) | $96.1M | 141,266 |
| 167 | Sevelamer Carbonate (Sevelamer Carbonate) | $95.6M | 277,192 |
| 168 | Aripiprazole Lauroxil (Aristada) | $93.3M | 31,120 |
| 169 | Trazodone Hcl (Trazodone Hcl) | $92.6M | 7,273,528 |
| 170 | Insulin Glargine/Lixisenatide (Soliqua 100-33) | $92.5M | 82,886 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology